Eric P Borrelli1, Blake Morphis2, Rouba Youssef3, Laura C Chambers4, Benjamin D Hallowell5, Jeffrey Bratberg6, Stephen J Kogut7. 1. PhD Candidate in Pharmaceutical Sciences, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island. 2. Director of Analytic Services, Healthcentric Advisors. 3. Health Information Analyst, Healthcentric Advisors. (during time of study). 4. Epidemiologist, Rhode Island Department of Health. 5. Biostatistician, Rhode Island Department of Health. 6. Clinical Professor, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island. 7. Professor of Pharmacy Practice; Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island.
Abstract
OBJECTIVE: To estimate the prevalence of concurrent prescription opioid and non-opioid controlled substance use in Rhode Island (RI). METHODS: We conducted a cross sectional observational study using data from the RI Prescription Drug Monitoring Program on controlled substance prescriptions dispensed in 2018. We estimated the prevalence of concurrent use of other prescribed controlled substances among adults who received at least one opioid prescription. RESULTS: In 2018, 142,692 RI adult residents received at least one opioid prescription, of whom 25.1% (99% confidence interval [CI]: 24.8-25.4) were concurrently prescribed at least one other controlled substance, including benzodiazepines (17.0%, 99% CI: 16.8-17.3), medications for insomnia (4.0%, 99% CI: 3.9-4.2), and stimulants (3.8%, 99% CI: 3.6-3.9). CONCLUSION: The concurrent use of prescription opioids and other prescribed controlled substances is common. Our findings suggest an urgent need to implement focused initiatives to address controlled substance polypharmacy to reduce the risk of overdose.
OBJECTIVE: To estimate the prevalence of concurrent prescription opioid and non-opioid controlled substance use in Rhode Island (RI). METHODS: We conducted a cross sectional observational study using data from the RI Prescription Drug Monitoring Program on controlled substance prescriptions dispensed in 2018. We estimated the prevalence of concurrent use of other prescribed controlled substances among adults who received at least one opioid prescription. RESULTS: In 2018, 142,692 RI adult residents received at least one opioid prescription, of whom 25.1% (99% confidence interval [CI]: 24.8-25.4) were concurrently prescribed at least one other controlled substance, including benzodiazepines (17.0%, 99% CI: 16.8-17.3), medications for insomnia (4.0%, 99% CI: 3.9-4.2), and stimulants (3.8%, 99% CI: 3.6-3.9). CONCLUSION: The concurrent use of prescription opioids and other prescribed controlled substances is common. Our findings suggest an urgent need to implement focused initiatives to address controlled substance polypharmacy to reduce the risk of overdose.
Authors: Nancy E Morden; Jeffrey C Munson; Carrie H Colla; Jonathan S Skinner; Julie P W Bynum; Weiping Zhou; Ellen Meara Journal: Med Care Date: 2014-09 Impact factor: 2.983
Authors: Yongwen Jiang; James V McDonald; Ariel Goldschmidt; Jennifer Koziol; Meghan McCormick; Samara Viner-Brown; Nicole Alexander-Scott Journal: R I Med J (2013) Date: 2018-09-04
Authors: Oriana Vesga-López; Franklin R Schneier; Samuel Wang; Richard G Heimberg; Shang-Min Liu; Deborah S Hasin; Carlos Blanco Journal: J Clin Psychiatry Date: 2008-09-23 Impact factor: 4.384
Authors: Shirley Musich; Shaohung S Wang; Luke B Slindee; Joann Ruiz; Charlotte S Yeh Journal: Popul Health Manag Date: 2019-11-25 Impact factor: 2.459
Authors: Anna Hung; Christopher Bush; Melissa Greiner; Hilary Campbell; Bradley Hammill; Matthew L Maciejewski; Aaron McKethan Journal: J Manag Care Spec Pharm Date: 2020-02
Authors: Meghna Jani; Nadyne Girard; David W Bates; David L Buckeridge; Therese Sheppard; Jack Li; Usman Iqbal; Shelly Vik; Colin Weaver; Judy Seidel; William G Dixon; Robyn Tamblyn Journal: PLoS Med Date: 2021-11-01 Impact factor: 11.069